Googe, JosephBrucker, Alexander JBressler, Neil MQin, HaijingAiello, LloydAntoszyk, AndrewBeck, Roy WBressler, Susan BFerris, Frederick LGlassman, Adam RMarcus, DennisStockdale, Cynthia R2018-04-132011Googe, Joseph, Alexander J Brucker, Neil M Bressler, Haijing Qin, Lloyd P Aiello, Andrew Antoszyk, Roy W Beck, et al. 2011. Randomized Trial Evaluating Short-Term Effects of Intravitreal Ranibizumab or Triamcinolone Acetonide on Macular Edema After Focal/grid Laser for Diabetic Macular Edema in Eyes Also Receiving Panretinal Photocoagulation. Retina 31, no. 6: 1009–1027. doi:10.1097/iae.0b013e318217d739.0275-004Xhttp://nrs.harvard.edu/urn-3:HUL.InstRepos:35769563Purpose: To evaluate 14-week effects of intravitreal ranibizumab or triamcinolone in eyes receiving focal/grid laser for diabetic macular edema (DME) and panretinal photocoagulation (PRP). Methods: Three hundred and forty-five eyes with a visual acuity of 20/320 or better, center-involved DME receiving focal/grid laser, and diabetic retinopathy receiving prompt PRP were randomly assigned to sham (n=123), 0.5-mg ranibizumab (n=113) at baseline and 4 weeks, or 4-mg triamcinolone at baseline and sham at 4 weeks (n=109). Treatment was at investigator discretion from 14 to 56 weeks. Results: Mean changes (±standard deviation) in visual acuity letter score from baseline were significantly better in the ranibizumab (+1±11, P<0.001) and triamcinolone (+2±11, P<0.001) groups compared with the sham group (-4±14) at the 14-week visit, mirroring retinal thickening results. These differences were not maintained when study participants were followed for 56 weeks for safety outcomes. One eye (0.9%, 95% CI: 0.02% to 4.7%) developed endophthalmitis after receiving ranibizumab. Cerebrovascular/cardiovascular events occurred in 4%, 7%, and 3% of the sham, ranibizumab, and triamcinolone groups, respectively. Conclusions: The addition of 1 intravitreal triamcinolone or 2 ranibizumab injections in eyes receiving focal/grid laser for DME and PRP is associated with better visual acuity and decreased macular edema by 14 weeks. Whether continued long-term intravitreal treatment is beneficial cannot be determined from this study.en-USproliferative diabetic retinopathydiabetic macular edemapanretinal photocoagulationranibizumabtriamcinolonerandomized clinical trialDiabetic Retinopathy Clinical Research NetworkJournal Article2018-04-1310.1097/IAE.0b013e318217d739